BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

NephroPlus raises Rs 850 Cr in Series F round from Quadria Capital

06 May 2024 | News

Quadriaâ??s partnership will support NephroPlus to grow its network in India and across Asia



Quadria Capital, one of Asia’s largest healthcare-focused private equity firms, has announced an investment of Rs 850 crore in Hyderabad-based NephroPlus, Asia’s largest dialysis network.

Through this transaction, Quadria will acquire a significant minority stake through a combination of a primary investment and the purchase of shares from existing shareholders. The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia.

Founded in 2010, NephroPlus is a uniquely positioned dialysis provider operating in sizeable, high-growth markets across Asia with dominant leadership in India and a fast-growing footprint in the Philippines and other Asian countries. The company serves patients across dialysis centres in marquee hospitals and at standalone clinics, working with leading nephrologists. NephroPlus also delivers care through public-private partnerships in both urban and rural areas.

Demand for dialysis services in the company’s target markets is expected to grow at a rate of over 11% annually over the next five years. Specialised chains such as NephroPlus are expected to gain market share as hospitals increasingly outsource dialysis operations and as governments seek to make high-quality dialysis services more accessible.

The company has a successful track record of growing via bolt-on acquisitions and plans to do more acquisitions in the future. With Quadria’s support, NephroPlus aims to leverage its strong brand, operational expertise, trusted relationships with leading nephrologists, to capitalise on growth opportunities and expand its market leadership.

Vikram Vuppala, Founder and CEO of NephroPlus, said, “We look forward to expanding in India, our core market, while exploring further opportunities to bring our expertise and clinical excellence to more patients in other global markets."